<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="147898">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01790087</url>
  </required_header>
  <id_info>
    <org_study_id>ANX-188-05</org_study_id>
    <nct_id>NCT01790087</nct_id>
  </id_info>
  <brief_title>ANX-188 Thorough QT/QTc Study in Healthy Volunteers</brief_title>
  <official_title>A Four Period, Four-Arm, Crossover Design, Randomized, Placebo and Active Controlled Study for the Evaluation of the Effect of Therapeutic and Supratherapeutic Single-Dose ANX-188 on the QT/QTc Intervals in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mast Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mast Therapeutics, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study has been designed in compliance with the ICH-E14 guideline (2005) to evaluate the
      effect of ANX-188 at therapeutic and supratherapeutic concentrations on cardiac
      repolarization, specifically, Fridericia's QT-Interval (QTcF)
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">June 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Evaluate the effect of therapeutic and supratherapeutic doses of ANX-188 on cardiac ventricular repolarization, specifically, the Fridericia's corrected QT-Interval (QTcF)</measure>
    <time_frame>Day 1 Pre-dose to 24 hours post-dose</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bazett's corrected QT-interval (QTcB)</measure>
    <time_frame>Pre-dose to 24 hours post-dose</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate measurements on treatment compared to time-matched baseline and placebo</measure>
    <time_frame>Pre-dose to 24 hours post-dose</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RR-interval on treatment compared to time-matched baseline and placebo</measure>
    <time_frame>Pre-dose to 24 hours post-dose</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QRS measurements on treatment compared to time-matched baseline and placebo</measure>
    <time_frame>Pre-dose to 24 hours post-dose</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PR interval measurements on treatment compared to time-matched baseline and placebo</measure>
    <time_frame>Pre-dose to 24 hours post-dose</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall characterization of normal and abnormal ECGs and the number and percentage of subjects with normal and abnormal ECGs</measure>
    <time_frame>Pre-dose to 24 hours post-dose</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and percentage of subjects that develop abnormalities of repolarization on treatment</measure>
    <time_frame>Pre-dose to 24 hours post-dose</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and percentage of subjects the develop abnormal U waves</measure>
    <time_frame>Pre-dose to 24 hours post-dose</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship between changes from the baseline and placebo in QTcF (DDQTcF)</measure>
    <time_frame>Pre-dose to 24 hours post-dose</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis for arrhythmias</measure>
    <time_frame>Pre-dose to 24 hours post-dsoe</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of ECG findings with clinical adverse events</measure>
    <time_frame>Pre-dose to 24 hours post-dose</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>ANX-188 Therapeutic dose level</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IV administration. 100 mg/kg for one hour followed by 30 mg/kg/hour for five hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ANX-188 Supratherapeutic dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IV administration.  300 mg/kg for one hour followed by 200 mg/kg/hr for five hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>IV administration.  Six hour infusion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Moxifloxacin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral tablet.  400 mg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ANX-188 Therapeutic Dose</intervention_name>
    <arm_group_label>ANX-188 Therapeutic dose level</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ANX-188 Supratherapeutic dose</intervention_name>
    <arm_group_label>ANX-188 Supratherapeutic dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <arm_group_label>Saline</arm_group_label>
    <other_name>Placebo Comparator</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxifloxacin</intervention_name>
    <arm_group_label>Moxifloxacin</arm_group_label>
    <other_name>Active Comparator</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male and female subjects aged 18 to 65 (inclusive) in good health as
             determined by past medical history, physical examination, vital signs,
             electrocardiogram, and laboratory testing at screening.

        Exclusion Criteria:

          -  Participation in a clinical trial within the last 60 days

          -  Pregnant or lactating females

          -  Use of prescription drugs, herbals, or over-the-counter medications within 14 days
             prior to study day -2

          -  Uncontrolled cardiac arrhythmias, cardiac valve abnormalities, or not in normal sinus
             rhythm

          -  Smokers or tobacco product user in the prior 3 months

          -  Presence of clinically significant illness

          -  Other protocol defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Santosh Vetticaden, PhD, MD</last_name>
    <role>Study Director</role>
    <affiliation>Mast Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>20201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <lastchanged_date>April 22, 2013</lastchanged_date>
  <firstreceived_date>February 11, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
